Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 Diabetes

Chiara Dalla Man, Gerlies Bock, Paula D. Giesler, Denise B. Serra, Monica Ligueros Saylan, James E. Foley, Michael Camilleri, Gianna Toffolo, Claudio Cobelli, Robert A. Rizza, Adrian Vella

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective-The purpose of this study was to determine the mechanism by which dipep-tidyl peptidase-4 inhibitors lower postprandial glucose concentrations. Research design and methods- We measured insulin secretion and action as well as glucose effectiveness in 14 subjects with type 2 diabetes who received vildagliptin (50 mg b.i.d.) or placebo for 10 days in random order separated by a 3-week washout. On day 9 of each period, subjects ate a mixed meal. Insulin sensitivity (SI), glucose effectiveness, and β-cell responsivity indexes were estimated using the oral glucose and C-peptide minimal models. At 300 min 0.02 unit/kg insulin was administered intravenously. Results- Vildagliptin reduced postprandial glucose concentrations (905 ± 94 vs. 1,008 ± 104 mmol/6 h, P = 0.02). Vildagliptin did not alter net S I (7.71 ± 1.28 vs. 6.41 ±0.84 10-4 dl · kg-1 · min-1 · (μU-1 · ml-1,P= 0.13) or glucose effectiveness (0.019 ± 0.002 vs. 0.018 ± 0.002 dl · kg-1 · min -1,P= 0.65). However, the net β-cell responsivity index was increased (35.7 ± 5.2 vs. 28.9 ± 5.2 10-9 min -1, P= 0.03) as was total disposition index (381 ± 48 vs. 261 ±35 10-14dl. kg-1 ·min -2-pmol-1 *l-1, P=0.006). Vildagliptin lowered postprandial glucagon concentrations (27.0 ±1.1 vs. 29.7 ± 1.5 (xg · l-1 · 6 h-1, P= 0.03), especially after administration of exogenous insulin (81.5 ± 6.4vs. 99.3 ± 5.6ng/l,P= 0.02). Conclusions-Vildagliptin lowers postprandial glucose concentrations by stimulating insulin secretion and suppressing glucagon secretion but not by altered insulin action or glucose effectiveness. A novel observation is that vildagliptin alters a-cell responsiveness to insulin administration, but the significance of this action is as yet unclear.

Original languageEnglish (US)
Pages (from-to)14-18
Number of pages5
JournalDiabetes Care
Volume32
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Dipeptidyl Peptidase 4
Type 2 Diabetes Mellitus
Meals
Eating
Insulin
Glucose
Glucagon
vildagliptin
C-Peptide
Protease Inhibitors
Insulin Resistance
Research Design
Placebos
Observation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 Diabetes. / Man, Chiara Dalla; Bock, Gerlies; Giesler, Paula D.; Serra, Denise B.; Saylan, Monica Ligueros; Foley, James E.; Camilleri, Michael; Toffolo, Gianna; Cobelli, Claudio; Rizza, Robert A.; Vella, Adrian.

In: Diabetes Care, Vol. 32, No. 1, 01.2009, p. 14-18.

Research output: Contribution to journalArticle

Man, Chiara Dalla ; Bock, Gerlies ; Giesler, Paula D. ; Serra, Denise B. ; Saylan, Monica Ligueros ; Foley, James E. ; Camilleri, Michael ; Toffolo, Gianna ; Cobelli, Claudio ; Rizza, Robert A. ; Vella, Adrian. / Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 Diabetes. In: Diabetes Care. 2009 ; Vol. 32, No. 1. pp. 14-18.
@article{07173fb30d1f4de98bca7cc469d2693c,
title = "Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 Diabetes",
abstract = "Objective-The purpose of this study was to determine the mechanism by which dipep-tidyl peptidase-4 inhibitors lower postprandial glucose concentrations. Research design and methods- We measured insulin secretion and action as well as glucose effectiveness in 14 subjects with type 2 diabetes who received vildagliptin (50 mg b.i.d.) or placebo for 10 days in random order separated by a 3-week washout. On day 9 of each period, subjects ate a mixed meal. Insulin sensitivity (SI), glucose effectiveness, and β-cell responsivity indexes were estimated using the oral glucose and C-peptide minimal models. At 300 min 0.02 unit/kg insulin was administered intravenously. Results- Vildagliptin reduced postprandial glucose concentrations (905 ± 94 vs. 1,008 ± 104 mmol/6 h, P = 0.02). Vildagliptin did not alter net S I (7.71 ± 1.28 vs. 6.41 ±0.84 10-4 dl · kg-1 · min-1 · (μU-1 · ml-1,P= 0.13) or glucose effectiveness (0.019 ± 0.002 vs. 0.018 ± 0.002 dl · kg-1 · min -1,P= 0.65). However, the net β-cell responsivity index was increased (35.7 ± 5.2 vs. 28.9 ± 5.2 10-9 min -1, P= 0.03) as was total disposition index (381 ± 48 vs. 261 ±35 10-14dl. kg-1 ·min -2-pmol-1 *l-1, P=0.006). Vildagliptin lowered postprandial glucagon concentrations (27.0 ±1.1 vs. 29.7 ± 1.5 (xg · l-1 · 6 h-1, P= 0.03), especially after administration of exogenous insulin (81.5 ± 6.4vs. 99.3 ± 5.6ng/l,P= 0.02). Conclusions-Vildagliptin lowers postprandial glucose concentrations by stimulating insulin secretion and suppressing glucagon secretion but not by altered insulin action or glucose effectiveness. A novel observation is that vildagliptin alters a-cell responsiveness to insulin administration, but the significance of this action is as yet unclear.",
author = "Man, {Chiara Dalla} and Gerlies Bock and Giesler, {Paula D.} and Serra, {Denise B.} and Saylan, {Monica Ligueros} and Foley, {James E.} and Michael Camilleri and Gianna Toffolo and Claudio Cobelli and Rizza, {Robert A.} and Adrian Vella",
year = "2009",
month = "1",
doi = "10.2337/dc08-1512",
language = "English (US)",
volume = "32",
pages = "14--18",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "1",

}

TY - JOUR

T1 - Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 Diabetes

AU - Man, Chiara Dalla

AU - Bock, Gerlies

AU - Giesler, Paula D.

AU - Serra, Denise B.

AU - Saylan, Monica Ligueros

AU - Foley, James E.

AU - Camilleri, Michael

AU - Toffolo, Gianna

AU - Cobelli, Claudio

AU - Rizza, Robert A.

AU - Vella, Adrian

PY - 2009/1

Y1 - 2009/1

N2 - Objective-The purpose of this study was to determine the mechanism by which dipep-tidyl peptidase-4 inhibitors lower postprandial glucose concentrations. Research design and methods- We measured insulin secretion and action as well as glucose effectiveness in 14 subjects with type 2 diabetes who received vildagliptin (50 mg b.i.d.) or placebo for 10 days in random order separated by a 3-week washout. On day 9 of each period, subjects ate a mixed meal. Insulin sensitivity (SI), glucose effectiveness, and β-cell responsivity indexes were estimated using the oral glucose and C-peptide minimal models. At 300 min 0.02 unit/kg insulin was administered intravenously. Results- Vildagliptin reduced postprandial glucose concentrations (905 ± 94 vs. 1,008 ± 104 mmol/6 h, P = 0.02). Vildagliptin did not alter net S I (7.71 ± 1.28 vs. 6.41 ±0.84 10-4 dl · kg-1 · min-1 · (μU-1 · ml-1,P= 0.13) or glucose effectiveness (0.019 ± 0.002 vs. 0.018 ± 0.002 dl · kg-1 · min -1,P= 0.65). However, the net β-cell responsivity index was increased (35.7 ± 5.2 vs. 28.9 ± 5.2 10-9 min -1, P= 0.03) as was total disposition index (381 ± 48 vs. 261 ±35 10-14dl. kg-1 ·min -2-pmol-1 *l-1, P=0.006). Vildagliptin lowered postprandial glucagon concentrations (27.0 ±1.1 vs. 29.7 ± 1.5 (xg · l-1 · 6 h-1, P= 0.03), especially after administration of exogenous insulin (81.5 ± 6.4vs. 99.3 ± 5.6ng/l,P= 0.02). Conclusions-Vildagliptin lowers postprandial glucose concentrations by stimulating insulin secretion and suppressing glucagon secretion but not by altered insulin action or glucose effectiveness. A novel observation is that vildagliptin alters a-cell responsiveness to insulin administration, but the significance of this action is as yet unclear.

AB - Objective-The purpose of this study was to determine the mechanism by which dipep-tidyl peptidase-4 inhibitors lower postprandial glucose concentrations. Research design and methods- We measured insulin secretion and action as well as glucose effectiveness in 14 subjects with type 2 diabetes who received vildagliptin (50 mg b.i.d.) or placebo for 10 days in random order separated by a 3-week washout. On day 9 of each period, subjects ate a mixed meal. Insulin sensitivity (SI), glucose effectiveness, and β-cell responsivity indexes were estimated using the oral glucose and C-peptide minimal models. At 300 min 0.02 unit/kg insulin was administered intravenously. Results- Vildagliptin reduced postprandial glucose concentrations (905 ± 94 vs. 1,008 ± 104 mmol/6 h, P = 0.02). Vildagliptin did not alter net S I (7.71 ± 1.28 vs. 6.41 ±0.84 10-4 dl · kg-1 · min-1 · (μU-1 · ml-1,P= 0.13) or glucose effectiveness (0.019 ± 0.002 vs. 0.018 ± 0.002 dl · kg-1 · min -1,P= 0.65). However, the net β-cell responsivity index was increased (35.7 ± 5.2 vs. 28.9 ± 5.2 10-9 min -1, P= 0.03) as was total disposition index (381 ± 48 vs. 261 ±35 10-14dl. kg-1 ·min -2-pmol-1 *l-1, P=0.006). Vildagliptin lowered postprandial glucagon concentrations (27.0 ±1.1 vs. 29.7 ± 1.5 (xg · l-1 · 6 h-1, P= 0.03), especially after administration of exogenous insulin (81.5 ± 6.4vs. 99.3 ± 5.6ng/l,P= 0.02). Conclusions-Vildagliptin lowers postprandial glucose concentrations by stimulating insulin secretion and suppressing glucagon secretion but not by altered insulin action or glucose effectiveness. A novel observation is that vildagliptin alters a-cell responsiveness to insulin administration, but the significance of this action is as yet unclear.

UR - http://www.scopus.com/inward/record.url?scp=64549119188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549119188&partnerID=8YFLogxK

U2 - 10.2337/dc08-1512

DO - 10.2337/dc08-1512

M3 - Article

VL - 32

SP - 14

EP - 18

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 1

ER -